Donna Cryer, JD Joins Clinical Trials Transformation Initiative Executive Committee


Contact: Jazmin Hampton, MPH

Donna Cryer, JD Joins Clinical Trials Transformation Initiative Executive Committee

Expert Patient Advocate Added to Public-Private Research Improvement Collaborative

May 24, 2018 – Washington, DC – The Clinical Trials Transformation Initiative (CTTI) has named Donna R. Cryer, JD to their Executive Committee as a patient advocacy representative. Mrs. Cryer currently serves as President and CEO of the Global Liver Institute, a patient-driven nonprofit organization fostering innovation and collaboration with diverse healthcare stakeholders to prevent, cure, and reduce the impact of liver diseases in the U.S. and internationally. A liver transplant recipient, Harvard graduate, and attorney, Mrs. Cryer brings decades of experience in clinical trial recruitment with diverse populations and developing principles of patient-centered research to the Committee. “CTTI recognizes the importance of meaningful patient engagement in both our organizational structure and project work, and in the broader clinical trials enterprise,” said CTTI Executive Director Pamela Tenaerts. “We are excited for Donna to serve on our Executive Committee and ensure that the patient voice is represented in decisions regarding CTTI’s direction and strategy.” “The opportunity to partner with CTTI to innovate the clinical research enterprise to more fully integrate patient perspectives and participation is unique and I eagerly accepted.”

CTTI’s Executive Committee includes distinguished U.S. and international thought leaders in government, academia, industry, and patient advocacy who are experienced at envisioning and facilitating improvements in health care and medical research systems. This Committee ensures that CTTI informs and facilitates meaningful improvements to the design and conduct of clinical trials. Members include: Mark McClellan, MD, PhD, Co-Chair (Duke –Margolis Center for Health Policy); John H. Alexander, MD, MHS, FACC, Co-Chair (Duke Clinical Research Institute); Jacqueline Corrigan-Curay, JD, MD (U.S. Food and Drug Administration); Dr. Hans-Georg Eichler (European Medicines Agency); Pat Furlong (Parent Project Muscular Dystrophy); Dalvir Gill, PhD (Transcelerate);  John Hubbard, PhD, FCP (Bioclinica); Kathy Hudson, PhD (People-Centered Research Foundation); Louis Jacques, MD (ADVI);  Richard Kuntz, MD, MSc (Medtronic);  Freda Lewis-Hall, MD (Pfizer); Virginia Nido, MS (Genentech);  Joe Selby, MD, MPH (Patient Centered Outcomes Research Institute;  Robert Temple, MD (FDA) ; and Bram Zuckerman, MD (FDA).

About the Clinical Trials Transformation Initiative (CTTI)

Clinical Trials Transformation Initiative (CTTI), a public-private partnership co-founded by Duke University and the U.S. Food and Drug Administration, seeks to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials. Comprised of more than 80 member organizations—representing academia, clinical investigators, government and regulatory agencies, industry, institutional review boards, patient advocacy groups, and other groups—CTTI is transforming the clinical trials landscape by developing evidence-based solutions to clinical research challenges. Many regulatory agencies and organizations have applied CTTI’s nearly 20 existing recommendations, and associated resources, to make better clinical trials a reality. Learn more about CTTI projects, recommendations, and resources at

About the Global Liver Institute

The Global Liver Institute is a 501(c)(3) tax exempt not-for-profit organization, headquartered in Washington, D.C., United States. Our Vision is for liver health to take its place on the global public health agenda commensurate with its prevalence and impact. Our Mission is to improve the effectiveness of the liver community by promoting innovation, collaboration, and scaling optimal approaches to eradicating liver disease. For more information see and connect with us on Twitter @GlobalLiver or Facebook